Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05099198 · ClinicalTrials.gov registry record
Replication of the GRADE Diabetes Trial in Healthcare Claims Data
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 6,403
- Enrollment target
NCT05099198: Completed study, sponsored by Brigham and Women's Hospital.
NCT05099198 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 6,403 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05099198 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 6,403 participants
- Enrollment target
Study Summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Primary Outcome
Lab based algorithm: time until failure to maintain metabolic control (HbA1c level \>= 7.0% or 53 mmol/mol)
Interventions
- DRUG Sitagliptin
- DRUG Glimepiride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,403 participants |
| Start Date | 2018-09-01 |
| Est. Completion | 2021-08-01 |
What the finished NCT05099198 record still lists
NCT05099198 is an observational study that tracks outcomes without assigning an intervention. Its 6,403 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Sitagliptin is the first listed.
NCT05099198 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05099198 about?
NCT05099198 is a clinical study titled "Replication of the GRADE Diabetes Trial in Healthcare Claims Data". Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such...
What is the current status of trial NCT05099198?
This trial is currently completed. The enrollment target is 6,403 participants. The study started on 2018-09-01. Estimated completion is 2021-08-01.
What interventions are being tested in trial NCT05099198?
The interventions under investigation include: Sitagliptin (DRUG), Glimepiride (DRUG).
Who is sponsoring clinical trial NCT05099198?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00505245 · 6,500 participants
New Assessment System in Measuring Symptom Distress in Cancer Patients
- NCT06821009 · 6,500 participants · NA
Effectiveness of a Cloud-based Digital Health Navigation Program for Colorectal Cancer Screening
- NCT05369429 · 6,516 participants · NA
My Wellbeing Guide: a Novel Tool for Managing Stress and Improving Quality of Life
- NCT04884802 · 6,254 participants · NA
The GUARDIAN Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI